168 related articles for article (PubMed ID: 28050196)
1. A Bioequivalence Test by the Direct Comparison of Concentration-versus-Time Curves Using Local Polynomial Smoothers.
Tian S; Chang HH; Orange D; Gu J; Suárez-Fariñas M
Comput Math Methods Med; 2016; 2016():4680642. PubMed ID: 28050196
[TBL] [Abstract][Full Text] [Related]
2. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence testing by statistical shape analysis.
Pereira LM
J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):451-84. PubMed ID: 17554610
[TBL] [Abstract][Full Text] [Related]
4. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
Chen YI; Huang CS
Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
[TBL] [Abstract][Full Text] [Related]
5. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
6. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
Agudelo M; Vesga O
Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin.
Sun HY; Liao HW; Sheng MH; Tai HM; Kuo CH; Sheng WH
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):347-351. PubMed ID: 27181716
[TBL] [Abstract][Full Text] [Related]
9. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
Liao JJ
Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
[TBL] [Abstract][Full Text] [Related]
10. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method.
Shen M; Machado SG
J Biopharm Stat; 2017; 27(2):257-264. PubMed ID: 27906608
[TBL] [Abstract][Full Text] [Related]
12. A new PK equivalence test for a bridging study.
Novick SJ; Zhang X; Yang H
J Biopharm Stat; 2016; 26(5):992-1002. PubMed ID: 26882145
[TBL] [Abstract][Full Text] [Related]
13. Generic lamotrigine extended-release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study.
Fang L; Li Z; Kinjo M; Lomonaco S; Zheng N; Jiang W; Zhao L
Epilepsia; 2023 Jan; 64(1):152-161. PubMed ID: 36259141
[TBL] [Abstract][Full Text] [Related]
14. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence studies for levothyroxine.
Bolton S
AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
18. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
Hammami MM; De Padua SJS; Hussein R; Al Gaai E; Khodr NA; Al-Swayeh R; Alvi SN; Binhashim N
BMC Pharmacol Toxicol; 2017 Dec; 18(1):78. PubMed ID: 29216899
[TBL] [Abstract][Full Text] [Related]
19. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons.
Gwaza L; Gordon J; Potthast H; Welink J; Leufkens H; Stahl M; García-Arieta A
Eur J Clin Pharmacol; 2015 Sep; 71(9):1083-9. PubMed ID: 26105964
[TBL] [Abstract][Full Text] [Related]
20. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
